• Mecamylamine is a racemic, non-selective nicotinic acetylcholine receptor antagonist approved for the treatment of malignant hypertension
  • Mecamylamine‚Äôs R-enantiomer, however, is thought to contribute to the anticholinergic/parasympathetic side effects of this therapy
  • AT-5214 (dexmecamylamine) is the S-enantiomer of mecamylamine, a selective inhibitor of the acetylcholine nicotinic receptor
  • AT-5214 is thought to inhibit the sympathetic ganglion with lessened parasympathetic side effects